Characteristics of patients with receiving GLM, according to the order of introduction
| Golimumab (GLM) RA-APS (n: 13) | 1°–2° anti-TNF (n: 7) | 3°–4° Anti-TNF (n: 6) | p |
|---|---|---|---|
| BMI, kg/m2: mean (SD) | 28,72 (6,62) | 28,93 (6,66) | 0,95 |
| Disease evolution (years): mean (SD) | 10,1 (7,64) | 11,53 (10) | 0,78 |
| DMARD, n (%) | 7 (100) | 4 (67) | 0,13 |
| Years on GLM: mean (SD) | 2,27 (1,86) | 2,5 (2,04) | 0,84 |
| anti-GLM Ab, U/L, n (%) | 0 | 0 | – |
| DAS28-VSG, mean (SD) | 1,74 (0,83) | 2,12 (0,94) | 0,47 |
| DAS28-PCR, mean (SD) | 1,82 (0,85) | 2,28 (0,93) | 0,39 |
| SDAI, mean (SD) | 3,92 (5,17) | 7,67 (6,58) | 0,30 |
| Golimumab (GLM) AS (n: 33) | 1°–2° anti-TNF (n: 21) | 3°–4° anti-TNF (n: 12) | p |
| BMI, kg/m2: mean (SD) | 27,46 (4,20) | 29,26 (3,09) | 0,16 |
| Disease evolution (years): mean (SD) | 14,25 (10,55) | 20,65 (14,27) | 0,21 |
| DMARD, n (%) | 8 (38%) | 2 (17) | 0,57 |
| Years on GLM: mean (SD) | 1,75 (1,47) | 1,13 (0,89) | 0,14 |
| GLM level, mg/dL: mean (SD) | 0,919 (0,63) | 0,448 (0,47) | 0,025 |
| anti-GLM Ab, U/L, n (%) | 0 | 2 (17) | – |
| BASDAI: mean (SD) | 5,96 (2,48) | 6,10 (2,23) | 0,86 |
| ASDAS: mean (SD) | 2,92 (0,87) | 3,79 (2,68) | 0,64 |